These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 322574)

  • 21. Immunotherapy of cancer.
    Holmes EC; Morton DL; Eilber FR
    West J Med; 1977 Feb; 126(2):102-9. PubMed ID: 322390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regression of a hamster melanoma with intralesional Corynebacterium granulosum.
    Paslin D
    Br J Dermatol; 1976 Jun; 94(6):639-44. PubMed ID: 949459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets.
    Zbar B; Ribi E; Meyer T; Azuma I; Rapp HJ
    J Natl Cancer Inst; 1974 May; 52(5):1571-7. PubMed ID: 4364736
    [No Abstract]   [Full Text] [Related]  

  • 24. Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Dec; 38(12):4522-6. PubMed ID: 719637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental and clinical trials with BCG immunotherapy.
    Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL
    Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024
    [No Abstract]   [Full Text] [Related]  

  • 26. Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin-induced granuloma formation in mice lacking CD4 and CD8.
    Senaldi G; Shaklee CL; Mak TW; Ulich TR
    Cell Immunol; 1999 May; 193(2):155-61. PubMed ID: 10222057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ; Reeson DE; Osborn TW; Boulger LR
    Dev Biol Stand; 1977 Apr 13-15; 38():363-8. PubMed ID: 608525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.
    Scott MT; Milas L
    Cancer Res; 1977 Jun; 37(6):1673-9. PubMed ID: 870181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antitumour activity of maltose tetrapalmitate compared with other immunoadjuvants, and its effectiveness after tumour surgery.
    El Kappany H; Chopra C; Nigam VN; Brailovsky CA; Elhilali M
    Br J Cancer; 1980 Nov; 42(5):703-11. PubMed ID: 7459208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
    Vanhaelen CP; Fisher RI
    Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined treatment of rodent fibrosarcoma by radiotherapy and immune adjuvant.
    Moroson H; Rotman M; Schechter M
    Int J Radiat Oncol Biol Phys; 1976; 1(3-4):267-74. PubMed ID: 786964
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunoregulation of antitumor response; differential secretion of arachidonic acid metabolites by macrophages during stimulation in vitro with BCG and Corynebacterium parvum.
    Tomecki J; Sukiennik J; Kordowiak A
    Arch Immunol Ther Exp (Warsz); 1993; 41(1):45-50. PubMed ID: 8239907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI.
    Senaldi G; Yin S; Shaklee CL; Piguet PF; Mak TW; Ulich TR
    J Immunol; 1996 Dec; 157(11):5022-6. PubMed ID: 8943410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of cancer in man.
    Carter SK
    Am Sci; 1976; 64(4):418-23. PubMed ID: 786091
    [No Abstract]   [Full Text] [Related]  

  • 36. Active non-specific immunotherapy of experimental tumours.
    Silobrcić V
    Folia Biol (Praha); 1980; 26(3):145-66. PubMed ID: 6998756
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro killing of schistosomula of Schistosoma mansoni by BCG and C. parvum-activated macrophages.
    Mahmoud AA; Peters PA; Civil RH; Remington JS
    J Immunol; 1979 May; 122(5):1655-7. PubMed ID: 376723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of glucan and other adjuvants on the clearance of radiolabeled tumor cells from mouse lungs.
    Proctor JW; Stiteler RD; Yamamura Y; Mansell PW; Winters R
    Cancer Treat Rep; 1978 Nov; 62(11):1873-80. PubMed ID: 728905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current state of clinical immunotherapy.
    Woodruff MF
    Transplant Proc; 1979 Mar; 11(1):1077-81. PubMed ID: 377611
    [No Abstract]   [Full Text] [Related]  

  • 40. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum.
    Yuhas JM; Ullrich RL
    Cancer Res; 1976 Jan; 36(1):161-6. PubMed ID: 1247995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.